X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
The net proceed will be used in the clinical development of Cytisinicline, which is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor and will using for Smoking Cessation in adult smokers.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Propel Bio Partners LLC
Deal Size: $124.2 million Upfront Cash: $60.0 million
Deal Type: Private Placement February 29, 2024
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is being evaluated for the treatment of smoking cessation and nicotine dependence.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The agreement aims to launch a clinical effectiveness study of its TBX-Free oral strips (cytisine) products, acts similarly to nicotine where it can stimulate receptors in the brain, for smoking and e-cigarette cessation.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: TBX-FREE
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Redwood Scientific Technologies Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2024
Details:
The proceeds will fund product development, including cytisinicline, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor believed to aid in treating nicotine addiction for smoking and e-cigarette cessation.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lake Street Capital
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2023
Details:
Cytisine (cytisiniclin)e is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
Cytisine (cytisiniclin)e is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve continues to pursue numerous patents that will further enhance the product’s stability and the potential for life cycle.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
ORCA-V1 is evaluating the efficacy and safety of cytisinicline in adult users of nicotine e-cigarettes or vapes. The study enrolled subjects who only used nicotine e-cigarettes, were not currently smoking combustible cigarettes, and who wanted to quit nicotine dependance.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. ORCA-V1 will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily compared to placebo.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
The grant award will provide funding that enables Achieve to initiate the Phase 2 ORCA-V1 clinical trial, which aims to evaluate the efficacy and safety of cytisinicline in approximately 150 adult nicotine e-cigarette users at 5 clinical trial locations in the United States
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding June 01, 2022
Details:
Subjects who received 12 weeks of cytisinicline treatment had 6.3 times higher odds to have quit smoking during last 4 weeks of treatment compared to subjects who received placebo. Abstinence rate during weeks 9-12 was 32.6% for cytisinicline compared to 7.0% for placebo.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor, is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
ORCA-2 participants will be randomized to one of three study arms to determine the smoking cessation efficacy and safety profile of cytisinicline administered for either 6 or 12 weeks, compared to placebo.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The study, conducted at the University of Cambridge Department of Biochemistry by Professor Sarah Lummis and Dr. Kerry Price, was designed to examine the in vitro binding characteristics of cytisinicline compared to varenicline at the human 5-HT3 receptor.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
Cytisinicline data will be featured in two presentations on Friday, September 18th, at the SRNT-E virtual conference. Both presentations evaluate positive findings from studies comparing cytisinicline to varenicline (Chantix®).
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Achieve intends to use the proceeds from the offering to fund clinical research and development, and for general working capital.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lake Street Capital Markets
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 04, 2020
Details:
Company submitted required non-clinical supportive data for longer cytisinicline treatment to the U.S. Food & Drug Administration (FDA) in preparation for Phase 3 cytisinicline ORCA-2 trial initiation.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
